Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Innovative Automated Insulin Delivery System for Type 2 Diabetes

NCT: NCT06853990 · COMPLETED

NCT IDNCT06853990
StatusCOMPLETED
Start Date2025-04-14
Completion2026-05-06
SponsorDeka Research and Development (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.

Frequently Asked Questions

What is Innovative Automated Insulin Delivery System for Type 2 Diabetes?

Innovative Automated Insulin Delivery System for Type 2 Diabetes is a clinical trial registered under NCT06853990. Current status: COMPLETED.

What is the status of NCT06853990?

The current status of NCT06853990 (Innovative Automated Insulin Delivery System for Type 2 Diabetes) is: COMPLETED.

When did Innovative Automated Insulin Delivery System for Type 2 Diabetes start?

Innovative Automated Insulin Delivery System for Type 2 Diabetes started on 2025-04-14.

Related Devices

K261672twiist Automated Insulin Delivery (AID) SystemDeka Research and Development K202690Remunity Pump for Remodulin (treprostinil) InjectionDeka Research and Development K213536DEKA ACE Pump SystemDeka Research and Development K232316DEKA Infusion System, DEKA Administration SetDeka Research and Development K233557HemoCare Hemodialysis SystemDeka Research and Development

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑